Abstract
Variants of Concern (VOC) of SARS-CoV-2, including Alpha, Beta, Gamma, Delta, and Omicron threaten to prolong the pandemic leading to more global morbidity and mortality. Genome sequencing is the mainstay of tracking the development and evolution of the virus, but is costly, slow, and not easily accessible. A multiplex qRT-PCR assay for SARS-CoV-2 was developed, which identifies all VOC as well as other mutations of interest in the viral genome, eight mutations total, using single nucleotide discriminating molecular beacons in a two-tube assay. The presented variant molecular beacon assay showed a limit of detection of five copies of the viral RNA, with 100% specificity. Twenty-six SARS-CoV-2 positive patient samples were blinded and tested using this assay. When testing patient samples, the assay was in full agreement with results from deep sequencing with a sensitivity and specificity of 100% (26/26). We have used our design methodology to rapidly design an assay which detects the new Omicron variant. This Omicron assay was used to accurately identify this variant in 17 of 33 additional patient samples. These qRT-PCR assays identify all currently circulating VOC of SARS-CoV-2 as well as other important mutations in its Spike protein coding sequence. These assays can be easily implemented on broadly available five-color thermal cyclers and will help track the spread of these variants.
Competing Interest Statement
D. Ashley Hill is the Medical Director of ResourcePath and Amanda P. Field, Alicia Brownlee, and Alex Cironi are employed by ResourcePath. ResourcePath partly funded this work through a grant to Rutgers. Ryan J. Dikdan, Salvatore A.E. Marras, and Sanjay Tyagi declare no conflicts of interests.
Funding Statement
This research was supported through a grant from NIH R01 CA227291 and a grant from ResourcePath, LLC.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study used archived, de-identified samples left over from clinical testing. The study received expedited approval with full waiver of consent, Advarra IRB# Pro00058476.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Conflicts of Interest: D. Ashley Hill is the Medical Director of ResourcePath and Amanda P. Field, Alicia Brownlee, and Alex Cironi are employed by ResourcePath. ResourcePath partly funded this work through a grant to Rutgers. Ryan J. Dikdan, Salvatore A.E. Marras, and Sanjay Tyagi declare no conflicts of interests.
Support: This research was supported through a grant from NIH R01 CA227291 awarded to ST and a grant from ResourcePath, LLC.
Additional data regarding accuracy when tested on inactivated viral samples as well as a new assay for identifying omicron variant.
Data Availability
All sequencing data is available in the mendeley data link. DOI: 10.17632/v3n2dzt8st.1
